Slide 1: Stock exchange filing cover letter for Investor Presentation
www.nureca.com Dated-21.07.2026 BSE LIMITED NATIONAL STOCK EXCHANGE OF INDIA Corporate Relations Department LIMITED Phiroze Jeejeebhoy Towers Listing Department Dalal Street, Fort Exchange Plaza, 5th Floor, Plot no. C/1 Mumbai-400001 G Block, Bandra Kurla Complex, Bandra (E) Scrip code: 543264 Mumba
Slide 2: Investor Presentation Q1 & FY'27 - Trusted for Life
Investor Presentation Q1 & FY’27 Trusted for Life Building India’s leading consumer healthcare platform across brands, connected devices, omnichannel distribution and manufacturing.
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Table of Contents
Table of Contents 1 The Quarter at a Glance 2 Financial Performance 3 About our Business 4 Growth & Outlook
Slide 5: The Quarter at a Glance
NURECA 1 The Quarter at a Glance
Slide 6: Dear Shareholders
Dear Shareholders, The operational turnaround we delivered in FY26 has carried into the new financial year. Our focus remains on profitable growth and disciplined cost management as we build out our consumer healthcare platform across healthcare, wellness and personal-care categories. Manufacturing
Slide 7: Q1 FY'27 Highlights
SECTION 1 · QUARTER AT A GLANCE Q1 FY'27 Highlights ₹ 40.3 Cr ₹ 51.8 Cr 38.8 % Revenue from Operations GMV Gross Margin ▲ 14% QoQ (Q4 FY 26: ₹35.4 Cr) · 18% YoY Q4 FY 26: ₹ 49.7 Cr 6 bps YoY ₹ 3.4 Cr ( 8.7% ) ₹ 4.43 Cr ( 10.5% ) ₹ 110 Cr Operating Profit / Margin Profit Before Tax Net Cash & Investm
Slide 8: Operating Profit → PBT Bridge (Q1 FY'27 Actuals)
Operating Profit → PBT Bridge (Q1 FY'27 Actuals) + ₹ 1.82 Cr − ₹ 0.20 Cr − ₹ 0.61 Cr ₹ 4.43 Cr Q1 FY'27 ₹ 3.42 Cr PBT ₹ 4.43 Cr 10.5% of revenue Operating Profit PBT Other Income Finance Cost Depreciation (8.5% of revenue) (10.1% of revenue)
Slide 9: Financial Performance
NURECA 2 Financial Performance
Slide 10: P&L Summary (Consolidated)
P&L Summary (Consolidated) ₹ Crore Q1' FY 27 Q4' FY 26 QoQ % Q1' FY 26 YoY % Revenue from operations 40.3 35.4 14% 34.2 18% Other Income 1.8 1.0 80% 2.6 -31% Total Revenue 42.1 36.4 16% 36.8 14% Total Expenses 36.9 41.1 -10% 34.8 6% Operating Profits 3.5 2.6 35% -0.6 683% EBITDA 5.2 -4.7 211% 2.0 16
Slide 11: KPI Trends
KPI Trends Revenue from Operations ( % Crore) 21-22 22-23 23-24 24-25 25-26 Qu FY27 EBITDA % T 24% 12% + 4% 5% 21-22 22-23 23-24 24-25 25-26 Qu FY27 48% 21-22 22-23 Gross Margin % 23-24 EPS (Earning Per Share) 24-25 0.9 25-26 2.1 NURECA Qu FY27 3.2 22-23 23-24 QU FY27
Slide 12: About our Business
NURECA 3 About our Business
Slide 13: Nureca at a Glance: A branded consumer healthcare platform
Nureca at a Glance A branded consumer healthcare platform Combining products, distribution, digital health and manufacturing Connected health Trusted consumer brands Omnichannel distribution Manufacturing-led growth ecosystem B D 360 M Expanding domestic Online marketplaces, quick Dr Trust and Dr Ph
Slide 14: Brand Range, Role and Key Product Categories
Brand Range Role Key Product Categories Example Products Vital monitoring, chronic care devices, connected Dr Trust Point of Care Monitoring and diagnosis at home BP monitors, glucometers, pulse oximeters, thermometers, nebulizers health devices Everyday fitness, body tracking, and Body metrics, act
Slide 15: Revenue by Channel
Revenue by Channel Trajectory Commentary • Ecommerce: Online Sales increased by 16% (YoY) & 5% (QoQ) results with category expansion and sustainability under existing categories • Offline Retail Network: revenue trend increased to 57% (YoY) & 14% (QoQ) coverage expands with super stockists and new d
Slide 16: Current Manufacturing base: quality, agility and control
Current Manufacturing base: quality, agility and control NTPL provides the operating foundation for a manufacturing-led growth 8 Lakh 15 Units annual capacity CDSCO approvals Existing Indian manufacturing capacity Quality clearances Categories manufactured at NTPL Mohali • BP monitors, nebulizers, t
Slide 17: Connected Health: Dr Trust 360 ecosystem
Connected Health: Dr Trust 360 ecosystem Smart Body composition scales, Blood Pressure Monitors, Kitchen Scales 2.4 Million AI App users Health insights Dr Trust 360 user base Trend detection and summaries Dr Trust 360 is Nureca’s connected-health platform, integrating smart devices, health data and
Slide 18: Growth & Outlook
NURECA 4l Growth & Outlook
Slide 19: The Story of Nureca
The Story of Nureca A journey of trust, innovation and impact 2016 2019 2021 2023 2025 • Birth of Nureca Revenue crosses USD 10 Mn — pure • Listed on NSE & BSE • Ranked “India's No.1 Home • USFDA-registration completed for • Dr Trust launched digitally e-commerce sales • Listed in ET Best Healthcare
Slide 20: Home Healthcare Products Market — India & Neighboring Countries
INDUSTRY LANDSCAPE Home Healthcare Products Market — India & Neighboring Countries Market size in ₹ Crore, 2025–2030E CAGR 2025–30E: 9.9% ₹5,203 Reading the Market 5,000 ₹4,727 ₹4,298 1,408 ₹3,911 1,315 • ₹3,240 Cr → ₹5,203 Cr by 2030E — a 1.6x 4,000 ₹3,559 market at 9.9% CAGR 1,228 289 ₹3,240 1,147
Slide 21: Thank You
Thank You THINK. FEEL. CREATE. Investor Relations: Nishu Kansal · investor@nureca.com Corporate: www.nureca.com · Ecommerce Store: www.drtrust.in Address : Andheri West B-205, Bldg 42, B-Wing, Dhanashree Heights, Azad Nagar Sangam CHS, Andheri West, Mumbai, Maharashtra, India - 400053